Metastat (OTCMKTS:MTST) and Prestige Consumer Healthcare (NYSE:PBH) Head to Head Survey

Metastat (OTCMKTS:MTST) and Prestige Consumer Healthcare (NYSE:PBH) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations and valuation.

Insider & Institutional Ownership

100.0% of Prestige Consumer Healthcare shares are held by institutional investors. 8.5% of Metastat shares are held by insiders. Comparatively, 1.4% of Prestige Consumer Healthcare shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations and price targets for Metastat and Prestige Consumer Healthcare, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metastat	0	0	0	0	0.00
Prestige Consumer Healthcare	0	4	4	0	2.50

Prestige Consumer Healthcare has a consensus target price of $85.33, suggesting a potential upside of 39.45%. Given Prestige Consumer Healthcare’s stronger consensus rating and higher possible upside, analysts plainly believe Prestige Consumer Healthcare is more favorable than Metastat.

Earnings & Valuation

This table compares Metastat and Prestige Consumer Healthcare”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metastat	N/A	N/A	N/A	N/A	N/A
Prestige Consumer Healthcare	$1.14 billion	2.59	$214.60 million	$4.03	15.18

Prestige Consumer Healthcare has higher revenue and earnings than Metastat.

Profitability

This table compares Metastat and Prestige Consumer Healthcare’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Metastat	N/A	N/A	N/A
Prestige Consumer Healthcare	18.09%	12.43%	6.67%

Volatility & Risk

Metastat has a beta of 288.02, indicating that its stock price is 28,702% more volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500.

Summary

Prestige Consumer Healthcare beats Metastat on 8 of the 10 factors compared between the two stocks.

About Metastat

MetaStat, Inc., a precision medicine company, focuses on discovering and developing therapeutic and diagnostic treatment solutions for cancer patients. The company is developing novel drug candidates and companion diagnostic tests that target the MENA pathway. Its product candidates include MENA diagnostic assay, a tissue-based quantitative immunofluorescence test that measures expression of the pro-metastatic MENA protein splice-variant; companion diagnostic to predict RTK inhibitor drug responses and anti-microtubule drug responses; liquid blood-based biopsy to enhance cancer diagnosis and optimize patient care; MetaSite Breast assay, an immunohistochemistry test that measures micro-anatomical intravasat at blood vessels within the tumor microenvironment ion sites; and prognostic diagnostic to predict risk of cancer metastasis. The company’s therapeutic targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. MetaStat, Inc. is based in Boston, Massachusetts.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.